HYDERABAD INDIA / Princeton, NJ, USA.: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Ziprasidone Mesylate for Injection, 20 mg (base)/mL Single-dose Vials, the therapeutic generic equivalent of Geodon® (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).
“We’re pleased to bring the first generic of Ziprasidone Mesylate for Injection to market for patients who will benefit from access to affordable medicine. With every new product launch, we believe we are making healthcare more affordable by delivering value to the pharmacy,” explains Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “This is a great addition to our injectable offering in the U.S. market as we continue to augment our portfolio and drive growth within the hospital segment.”
The Geodon® brand had U.S.
sales of approximately $21.8 million MAT for the most recent twelve months
ending in January 2020 according to IQVIA Health*.
Please see full Prescribing Information including boxed warning.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Sign me up for the newsletter!
Notify me of follow-up comments by email.
Notify me of new posts by email.
CREDAI Signs MOU with Institute of Indian Interior Designers
Flipkart encourages greater employee involvement and commitment to its sustainability vision on World Environment Day
Ecom Express appoints Amit Kumar as Lead – Environment Health & Safety
NMDC believes in nurturing nature for nurturing future
Coronavirus (COVID-19): scientific evidence supporting the UK government response
2014 The Global Indian New Network (TGINN)